Boehringer Ingelheim and Circle Pharma have signed a partnership and licence agreement focused on developing a new cancer ...

Boehringer Ingelheim, in partnership with the WHO Foundation [an organisation set up to support the World Health Organization ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

She's currently the Chief Medical Officer and Head of Medicine at Boehringer Ingelheim. Well, Dr. Hinsch Gylvin. Thanks for joining me today. That really has changed. So first and foremost ...

With new phase 3 data in hand, Boehringer Ingelheim is preparing to file for approval of nerandomilast, a would-be successor to its blockbuster idiopathic pulmonary fibrosis (IPF) therapy Ofev.

By Noah Weiland and Rebecca Robbins Hikma said it had reduced the cash portion of the offer as Boehringer Ingelheim’s generic drugs business in the U.S. had lower-than-expected sales.

Tracking patient response to DMARD therapy has the potential to improve remission, but multiple barriers must be overcome ...

A persistent, often progressive, lung disease, COPD results from chronic inflammation that leads to structural changes ...

In 2020, the Food and Drug Administration asked drugmakers to pull Zantac and its generic versions off the market after a ...

Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO ... IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. The company was founded ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...